Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059078 | 0.92 | CYP2D6 (0.60) | ACHECYP2D6TAAR1HRH3NOS1 | |
| SCHEMBL3066066 | 0.87 | ACHE (0.59) | ACHECYP2D6TAAR1NOS1NOS2 | |
| SCHEMBL21657552 | 0.86 | KDM4E (0.54) | ACHECYP2D6TAAR1HRH3CHRNB2 | |
| SCHEMBL12844412 | 0.86 | CYP2D6 (0.53) | CYP2D6HRH3CHRNB2CHRNA4KCNH2 | |
| SCHEMBL10950517 | 0.84 | ACHE (0.54) | ACHECYP2D6TAAR1HRH3CHRNB2 | |
| SCHEMBL9166584 | 0.83 | DHFR (0.51) | CYP2D6KCNH2 | |
| SCHEMBL4297942 | 0.83 | MEP1B (0.50) | CYP2D6HRH3CHRNB2CHRNA4NOS1 | |
| SCHEMBL16858365 | 0.83 | CHRNB2 (0.67) | CHRNB2CHRNA4NOS1NOS2 | |
| SCHEMBL10235885 | 0.81 | KMT2A (0.54) | CYP2D6KCNH2BCHE | |
| SCHEMBL11245203 | 0.81 | LTA4H (0.59) | TAAR1HRH3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101939326-B | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN UNIVERSITY | 2013-06-05 | — | — | CN | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| CN-101939326-A | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN | 2011-01-05 | — | — | CN | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | ACHE 3877/4885CYP2D6 1178/4885TAAR1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.